Liposomal amphotericin B-the past

R. J. Brüggemann, G. M. Jensen, C. Lass-Flörl

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

10 Citaten (Scopus)


The discovery of amphotericin B, a polyene antifungal compound, in the 1950s, and the formulation of this compound in a liposomal drug delivery system, has resulted in decades of use in systemic fungal infections. The use of liposomal amphotericin B formulation is referenced in many international guidelines for the treatment of fungal infections such as Aspergillus and cryptococcal disease and Candida infections, as well as other less common infections such as visceral leishmaniasis. With the development of liposomal amphotericin B, an improved therapeutic index could be achieved that allowed the attainment of higher drug concentrations in both the plasma and tissue while simultaneously lowering the toxicity compared with amphotericin B deoxycholate. In over 30 years of experience with this drug, a vast amount of information has been collected on preclinical and clinical efficacy against a wide variety of pathogens, as well as evidence on its toxicity. This article explores the history and nature of the liposomal formulation, the key clinical studies that developed the pharmacokinetic, safety and efficacy profile of the liposomal formulation, and the available microbiological data.

Originele taal-2Engels
Pagina's (van-tot)ii3-ii10
TijdschriftJournal of Antimicrobial Chemotherapy
Nummer van het tijdschriftSuppl_2
StatusGepubliceerd - 25 nov. 2022
Extern gepubliceerdJa


Duik in de onderzoeksthema's van 'Liposomal amphotericin B-the past'. Samen vormen ze een unieke vingerafdruk.

Citeer dit